

GD 04/03312



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 21 SEP 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated 9 September 2004



04AUG03 E827617-1 D02884
P01/7700 0.00-0318205.2



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

P34236-/JDU/MCM/SCR

2. Patent application number

(The Patent Office will fill in this part)

0318205.2

2 AUG 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Albachem Limited
Elvingston Science Centre
By Gladsmuir
East Lothian
EH33 1EH
16 Charlotte Square
Edinburgh
EH2 4DF

Patents ADP number (if you know it)

8641797002

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

"Synthetic Method"

5. Name of your agent (if you have one)

Murgitroyd & Company

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

165-169 Scotland Street
GLASGOW
G5 8PL

Patents ADP number (if you know it)

~~1198015~~

1198015

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

12

Claim(s)

3

Abstract

-

Drawing(s)

3

+ 3 *fr.*

10. If you are also filing any of the following, state how many against each item.

Priority documents

-

Translations of priority documents

-

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

-

Request for preliminary examination and search (*Patents Form 9/77*)

-

Request for substantive examination (*Patents Form 10/77*)

-

Any other documents (*please specify*)

-

11.

I/We request the grant of a patent on the basis of this application.

Signature *Murgitroyd & Co.*

Date

1 August 2003

Murgitroyd & Company

12. Name and daytime telephone number of person to contact in the United Kingdom

Sophie Coret

0141 307 8400

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

1 Synthesis

2
3 The chemical synthesis of peptides up to 40
4 residues is now routinely efficient and recent
5 advances over the last 10 years has led to the
6 synthesis of peptides and small proteins in the
7 range of 40-150 residues. Efficient novel
8 synthetic methodology and a wide array of resins
9 which can be used for synthesis have contributed to
10 this.

11
12 One particular resin, developed by Wang, S.S.
13 *J.Amer.Chem.Soc.* 95, (1973), 1328, (see figure 1)
14 has become the industry standard which has proven
15 effective in the efficient synthesis of long
16 peptides. There are however a number of problems
17 with this resin which relate to the C-terminal
18 amino acid. Firstly esterification of the resin
19 with protected derivatives of cysteine and
20 histidine can cause significant levels of
21 racemisation which, of course, is highly
22 undesirable. Further, whilst esterification with

1 protected derivatives of proline is successful
2 problems are encountered after an additional amino
3 acid residue is added to form a dipeptide.
4 Deprotection of the dipeptide in preparation for
5 the coupling of the third amino acid gives a free
6 amino dipeptide ester which often cyclises
7 internally to form the free cyclic dipeptide (a
8 diketopiperazine) shown in figure 2. The resultant
9 loss of dipeptide is in most cases quantitative and
10 renders use of the Wang resin unsuitable for the
11 synthesis of C-terminal proline peptides. Moreover
12 it has also been suggested that cyclisation also
13 occurs when the penultimate C-terminal residue is a
14 proline residue or one of its derivatives.

15
16 The use of the sterically hindered and extremely
17 acid labile 2-chlorotrityl chloride resin (see
18 figure 3) is recommended for the synthesis of C-
19 terminal proline containing peptides (as the steric
20 bulk inhibits diketopiperazine formation).

21
22 Experiments were carried out to synthesise medium
23 length and long peptides where, due to the nature
24 of the C-terminal residue, 2-chlorotrityl resin was
25 used. The medium length peptide (about 30 residues)
26 was HNP-1 where the C-terminal residue is cysteine
27 The long peptide was guinea pig eotaxin, a 74 amino
28 acid peptide, of which the C-terminal residue is
29 proline.

30
31 Both experiments were unsuccessful. Low yields of
32 both peptides were obtained and monitoring of the

1 chain assembly showed a low coupling efficiency in
2 both cases. By comparison with the situation when
3 the HNP-1 peptide was synthesised on a Wang resin
4 using a resin loading procedure that was reported
5 to alleviate the problem of racemisation of C-
6 terminal cysteine, the chain assembly proved
7 excellent and the low yield obtained with the
8 chlorotrityl resin was ascribed to some property of
9 that resin.

10

11 One theory was that the extreme acid lability of
12 this resin led to a premature cleavage of the
13 peptide from the resin during chain assembly. The
14 inventors varied the conditions of synthesis to try
15 to eliminate the contact of the resin with acid
16 species during chain assembly of guinea pig eotaxin
17 but no improvement in yield was achieved. Another
18 theory is that some property of the 2-chlorotrityl
19 resin, e.g. swelling characteristics, renders it
20 unsuitable and inefficient in the assembly of long
21 peptides.

22

23 Thus 2-chlorotrityl resin appears only compatible
24 with the synthesis of relatively short (e.g. <20
25 residues) peptides. It has now been found that the
26 problems associated with respect to a peptide
27 containing a C-terminal proline on 2-chlorotrityl
28 resin can be alleviated if the synthesis is carried
29 out on the Wang resin.

30

31

32

1 **Summary of the Invention**

2

3 The invention relates to a method for synthesis of
4 a given peptide which contains a proline or one of
5 its derivatives, at proximity to, or at, the C-
6 terminus end of the peptide of interest. This
7 method is particularly suitable for the synthesis
8 of long peptides, for example peptides which have
9 at least 20 amino acid residues or for peptides
10 where synthesis is problematic on 2-
11 chlorotriethylchloride resin.

12

13 By the expression "proximity to" it is meant that
14 the proline residue is positioned at the
15 penultimate C-terminal position.

16

17 The expression "derivatives" is directed to a
18 peptide, an amino acid or an amino acid residue
19 which may differ from the corresponding peptide
20 amino acid or residue by the substitution/addition
21 of various substituents. It is usual in protein
22 synthesis to use modified amino acids having
23 protecting groups or which have been modified so as
24 to be able to act as labels or tags or for other
25 desirable purposes. For example, in the method of
26 the present invention amino acid derivatives such
27 as hydroxyproline or other proline derivatives
28 could be used.

29

30 In a preferred embodiment, the method comprises the
31 steps of:

- 1 a) synthesising on a first resin a C-
- 2 terminal portion of said peptide, or its
- 3 derivative, comprising at least three
- 4 successive amino acid residues or their
- 5 derivatives, by successive coupling of
- 6 selected amino acids, small peptides or
- 7 their derivatives, said first resin being
- 8 suitable for the formation of peptides
- 9 having a proline residue or a proline
- 10 derivative positioned at, or at proximity
- 11 of, the C-terminal end of said peptide;
- 12 b) cleaving the C-terminal portion thus
- 13 obtained from said first resin;
- 14 c) reattaching said C-terminal portion to a
- 15 second resin which is generally suitable
- 16 for the synthesis of peptides but is
- 17 unsuitable for the formation of peptides
- 18 having a proline residue or a proline
- 19 derivative positioned at, or at proximity
- 20 of, the C-terminal end of said peptide;
- 21 and
- 22 d) coupling selected amino acids, small
- 23 peptides or derivatives to the C-terminal
- 24 portion to obtain said given peptide.

25
26 Whilst peptides of any length can be synthesised
27 using the method of the invention, the method is
28 particularly suited for the synthesis of peptides
29 having at least 20 amino acid residues or "long
30 peptides". The method is particularly suitable for
31 peptides having up to about 150 amino acid
32 residues.

1 The method of the invention allows synthesis of
2 peptides which were otherwise difficult to obtain
3 quantitatively. Amongst such peptides which have a
4 C-terminal proline residue and can be obtained
5 using the method of the invention chemokines are of
6 particular interest and particularly the human
7 chemokines IP-10, BLC and MCP-2.

8
9 Advantageously, the first resin is chosen so that
10 it does not lead to the formation of cyclic
11 dipeptides and in particular to the formation of
12 diketopiperazine compounds.

13
14 Step a) and/or d) of the method of the invention
15 may be achieved by successive coupling of the
16 predetermined amino acid residues, small peptides
17 or their derivatives. This can be carried out
18 using standard solid phase procedures which are
19 well known. In these procedures, the α -amino group
20 of the next selected amino acid or small peptide is
21 protected using a protecting group and is added to
22 the resin bearing the C-terminal portion of the
23 peptide together with a coupling agent like
24 diisopropylcarbodiimide (DIC) or
25 dicyclohexylcarbodiimide (DCC). The α -amino
26 protecting group is then removed by exposure to a
27 suitable base which leaves the peptide bond intact
28 and the next amino residue can then be added by
29 repeating the above step. Such procedures are
30 detailed for example in W.C. Chan and P.D. White,
31 Fmoc Solid Phase Peptide Synthesis A Practical
32 Approach, OUP 2000.

1 A preferred first resin for the formation of the C-
2 terminal portion is the 2-chlorotrityl chloride
3 resin or any similar resin which inhibits or
4 minimises the formation of diketopiperazine.

5
6 A preferred resin to be used as the second resin
7 for synthesis of a long peptide which can be used
8 in the method of the invention is a resin having
9 benzyl ester linker like the 4-(3-methoxy-4-
10 (hydroxymethyl)phenoxyethyl) derivative of
11 polystyrene-co-divinylbenzene which is marketed
12 under the Trade Mark SASRINTM. A particularly
13 preferred resin is a 4-Hydroxymethylphenoxyethyl
14 resin known as Wang resin. Wang resins are well
15 known and widely available.

16
17 Advantageously, the cleaving step from the first
18 resin is achieved using a mild acid treatment, for
19 example 20% trifluoroethanol in dichloromethane.
20 This allows a fully protected (tri-) peptide moiety
21 to be obtained. Thus, the C-terminal portion can
22 be provided fully protected so it can be coupled
23 directly onto the resin suitable for synthesis of a
24 long peptide. The protective groups may be the
25 standard protective groups usually used in Fmoc (9-
26 fluorenylmethoxycarbonyl), Nsc (2-(4-
27 nitrophenylsulfonyl)ethoxycarbonyl) or t-Boc (ter-
28 butyloxycarbonyl) peptide synthesis.

29

30 The invention will now be described by way of
31 example only, with respect to figures in which:

32

1 Figure 1: shows molecular structure of the Wang
2 resin linker.

3 Figure 2: shows formation of diketopiperazine.
4

5 Figure 3: shows molecular structure of the 2-
6 chlorotrityl chloride resin linker.
7

8 **Example**

9

10 The synthesis of guinea pig eotaxin, which contains
11 a C-terminal proline residue, has been achieved
12 using this resin exchange technique with an overall
13 yield of 5mg following purification and disulphide
14 bond formation. When one considers that the same
15 scale synthesis performed on a 2-chlorotrityl resin
16 typically yields < 1mg overall, the advantages of
17 the method according to the invention are clearly
18 evident.
19

20 Any protein/peptide susceptible to diketopiperazine
21 formation can be assembled using this described
22 strategy. Polypeptides or proteins that contain
23 proline or proline derivatives at, or adjacent to,
24 the C-terminus are susceptible to diketopiperazine
25 formation during assembly. The described approach
26 will be extremely enabling for the synthesis of
27 such peptides.
28

29 Synthesis of gp eotaxin protected C-terminal
30 tripeptide on 2-chlorotrityl resin (Fmoc-Thr(Bu^t)-
31 Lys(Boc)-Pro-ClTrtR) (1)
32

1 Peptide synthesis was carried out on the ABI 430A
2 peptide synthesiser. H-Pro-2-chlorotrityl resin
3 (1g, 0.49mmol/g, Lot no. PrT-2, Nankai Hecheng Co.
4 Ltd., China) was used in the reaction vessel. Nsc-
5 Lys(Boc)-OH (503mg, 1mmol) was activated with HOCT
6 (4ml, 1mmol, GL Biochem, (Shanghai) Ltd. China) and
7 DIC (4ml, 1mmol, Acros) for 15mins then transferred
8 to the reaction vessel and coupled for 30mins. A
9 second cartridge of Nsc-Lys(Boc)-OH was activated
10 similarly and recoupled to the resin after draining
11 the first solution.

12

13 Following capping of unreacted amino groups on the
14 resin with acetic acid anhydride (0.5M in DMF,
15 10ml) the Nsc group was removed with Deblock
16 solution (1% DBU, 20% piperidine in DMF).

17

18 Fmoc-Thr(But)-OH (397mg, 1mmol, Applied Biosystems)
19 was activated in the same manner and coupled to the
20 resin for 30mins followed by recoupling of the same
21 amino acid as before. After coupling the resin was
22 washed with DMF then DCM and dried under vacuum
23 giving a yield of 1.21g of (1).

24

25 The synthesis was repeated using a further gram of
26 resin furnishing 1.18g of the title resin. The
27 resin batches were combined for further work.

28

29 Cleavage and isolation of Fmoc-Thr(Bu^t)-Lys(Boc)-
30 Pro-OH (2)

31

1 The peptide resin (1) was stirred in a solution of
2 trifluoroethanol (20%) in DCM (50ml) for 60mins.
3 The resin turned dark green. The solution was
4 filtered and evaporated under reduced pressure to
5 give an oil which was triturated with cold diethyl
6 ether / hexane. The solvent was evaporated and
7 fresh hexane added to yield a solid from which the
8 solvent was again removed by evaporation. A white
9 solid (400mg, 0.55mmol) was obtained. Mass
10 spectroscopy Electrospray positive ion found 723.4,
11 expected for $C_{39}H_{54}N_4O_9$ 722.4 kD.

12
13 Coupling of (2) to Wang resin to give Fmoc-
14 Thr(Bu^t)-Lys(Boc)-Pro-O-Wang resin (3)

15
16 The protected tripeptide (2) (400mg, 0.55mmol) was
17 dissolved in the minimum volume of DMF (<2ml) and
18 activated by the addition of DIC (86μl, 0.55mmol)
19 and sonicated for 15mins.

20
21 Wang resin (800mg, 0.56mmol/g, Lot no. W-34,
22 Nankai Hecheng Co. Ltd., China) was swollen in the
23 minimum volume of DMF until just freely mobile and
24 dimethylamino pyridine (a few crystals) added. The
25 activated peptide solution (2) was added and the
26 coupling reaction sonicated for 4h. The mixture
27 was then filtered and the resin washed with DMF,
28 DCM and diethyl ether successively. The resin was
29 dried under vacuum to give a final yield of 1.0g.
30 The Fmoc loading test was carried out on the resin
31 and a final loading of 0.162mmol/g was determined.
32 It was established using Izumiya test that the

1 loading of the tripeptide onto the Wang resin was
2 racemisation free.

3

4 Synthesis of gp eotaxin on Wang resin

5

6 The synthesis of gp eotaxin was carried out using
7 500mg, 0.081mmol of resin (3). Standard coupling
8 cycles using 1mmol of amino acid (HOCT 2ml, 1mmol)
9 and DIC (2ml, 1mmol) were carried out on the ABI
10 synthesiser with the exception that:

- 11 a) the next amino acid Fmoc-Thr(Trt)-OH was
12 coupled without a prior capping step on
13 the resin and
14 b) the N-terminal amino acid Fmoc-His(Trt)-
15 OH was coupled using HOBt 2mmol in place
16 of HOCT.

17

18 The final Fmoc group was retained on the resin as a
19 purification tag.

20

21 Cleavage, purification and isolation of gp eotaxin

22

23 After chain assembly, the Fmoc-peptide was cleaved
24 with EDT/H₂O/TIS/thioanisole/ TFA
25 (0.5/1.0/0.2/0.2/10ml) at 0°C under nitrogen for
26 4h. The resin was removed by filtration and peptide
27 precipitated into cold ether and centrifuged. It
28 was purified by G50 Sephadex gel filtration and
29 HPLC and the amino terminal Fmoc group cleaved from
30 the protein using 20% piperidine in CH₃CN/H₂O
31 (1:1). DTT was added to reduce the side chain of
32 Cys residues and the cleaved Fmoc removed by gel

1 filtration to give the pure, reduced peptide. This
2 was folded in 50mM Tris pH8.0, 5mM GSH/0.5mM GSSG,
3 and monitored by HPLC. Folding took about a week
4 to complete.

5

6 The folded peptide was purified by HPLC, to give
7 the pure, folded peptide. (Electrospray mass
8 spectrometry; Expected mass 8356.9 Da, found 8353.9
9 Da).

10

1 Claims

- 2
- 3 1. A method for synthesising a given peptide or
- 4 its derivative which contains a proline
- 5 residue or a proline derivative, at proximity
- 6 to, or at, the C-terminal end of said peptide,
- 7 the method comprising the steps of:
- 8 a) synthesising on a first resin a C-
- 9 terminal portion of said peptide, or its
- 10 derivative, comprising at least three
- 11 successive amino acid residues or their
- 12 derivatives, by successive coupling of
- 13 selected amino acids, small peptides or
- 14 their derivatives, said first resin being
- 15 suitable for the formation of peptides
- 16 having a proline residue or a proline
- 17 derivative positioned at, or at proximity
- 18 of, the C-terminal end of said peptide;
- 19 b) cleaving the C-terminal portion thus
- 20 obtained from said first resin;
- 21 c) reattaching said C-terminal portion to a
- 22 second resin which is generally suitable
- 23 for the synthesis of peptides but is
- 24 unsuitable for the formation of peptides
- 25 having a proline residue or a proline
- 26 derivative positioned at, or at proximity
- 27 of, the C-terminal end of said peptide;
- 28 and
- 29 d) coupling selected amino acids, small
- 30 peptides or derivatives to the C-terminal
- 31 portion to obtain said given peptide.
- 32

- 1 2. The method of Claim 1 wherein said peptide is
2 a long peptide.
3
- 4 3. The method of Claim 1 or 2 wherein said given
5 peptide is a chemokine having a proline
6 residue or a proline derivative at the C-
7 terminal or at proximity thereof.
8
- 9 4. The method of any one of Claims 1 to 3,
10 wherein said first resin is chosen so that it
11 does not lead to the formation of cyclic
12 dipeptide and in particular diketopiperazine
13 compounds.
14
- 15 5. The method of any one of Claims 1 or 4,
16 wherein said step a) and/or d) is achieved by
17 successive coupling of the predetermined amino
18 acid residues or derivatives.
19
- 20 6. The method of any one of Claims 1 to 5,
21 wherein said first resin for the formation of
22 the C-terminal portion is the 2-chlorotrityl
23 chloride resin.
24
- 25 7. The method of any one of Claims 1 to 6,
26 wherein said second resin is a resin of the
27 type having benzyl ester linkers.
28
- 29 8. The method of any one of Claims 1 to 7,
30 wherein said second resin is a Wang type
31 resin.
32

- 1 9. The method of any one of Claims 1 to 8,
2 wherein said given peptide as up to 150 amino
3 acid residues.
4
- 5 10. The method of any one of Claims 1 to 9,
6 wherein the cleaving step is achieved using a
7 mild acid treatment, for example 20%
8 trifluoroethanol in dichloromethane.
9
- 10 11. The method of any one of Claims 1 to 10,
11 wherein the C-terminal portion is fully
12 protected so it can be attached directly onto
13 the second resin.
14
15

Figure 1






Figure 2



Diketopiperazine formation during synthesis of C-terminal proline containing peptides

Figure 3



2-chlorotrityl chloride resin